Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
citalopram + mianserin
- Development stage
- Preclinical
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two antidepressants with different mechanisms of action. Citalopram is a selective serotonin reuptake inhibitor (SSRIs) that works by inhibiting serotonin reuptake, while mianserin is a tetracyclic antidepressant that acts as an antagonist at various receptors including α2-adrenergic receptors. The combination may provide complementary effects through different mechanisms and potentially reduce certain side effects.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT allosteric site (Serotonin transporter allosteric site)HRH1 (Histamine H1 Receptor)ADRA2A (α2A)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on citalopram + mianserin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on citalopram + mianserin.